1921
Volume 84, Issue 2_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Frequency and levels of IgG antibodies to an N-terminal fragment of the MSP-1 (200L) protein, in individuals naturally exposed to malaria in four endemic areas of Brazil, were evaluated by enzyme-linked immunosorbent assay. Plasma samples of 261 -infected individuals from communities of Macapá, Novo Repartimento, Porto Velho, and Plácido de Castro in the Amazonian region with different malaria transmission intensities. A high mean number of studied individuals (89.3%) presented with antibodies to the 200L that correlated with the number of previous malaria infections; there were significant differences in the frequency of the responders (71.9–98.7) and in the antibody levels (1:200–1:51,200) among the four study areas. Results of this study provide evidence that 200L is a naturally immunogenic fragment of the MSP-1 and is associated with the degree of exposure to parasites. The fine specificity of antibodies to 200L is currently being assessed.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2011.10-0044
2011-02-04
2017-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/84/2_Suppl/58.html?itemId=/content/journals/10.4269/ajtmh.2011.10-0044&mimeType=html&fmt=ahah

References

  1. Feachem RG, , The Malaria Elimination Group, 2009. Shrinking the Malaria Map: A guide on Malaria Elimination for Policy Makers. San Francisco, CA: The Global Health Group, University of California, 85.
  2. Mendis K, Sina BJ, Marchesini P, Carter R, , 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97106.
  3. Brazilian Health Ministry, 2007. Epidemiological survey of malaria in Brazil. Secretariade Vigilanciaem Saúde/Ministérioda Saúde, ed., Saúde, Brasil.
  4. WHO, 2008. World Malaria Report. Geneva, Switzerland.
  5. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, Druilhe P, Giersing BK, Saul A, Heppner DG, Kester KE, Lanar DE, Lyon J, Hill AV, Pan W, Cohen JD, , 2004. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 71: 239247.
  6. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, Williams TN, Marsh K, Beeson JG, , 2008. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum . PLoS ONE 3: e3571.[Crossref]
  7. Nogueira PA, Alves FP, Fernandez-Becerra C, Pein O, Santos NR, Pereira da Silva LH, Camargo EP, del Portillo HA, , 2006. A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect Immun 74: 27262733.[Crossref]
  8. O'Meara WP, Mwangi TW, Williams TN, McKenzie FE, Snow RW, Marsh K, , 2008. Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg 79: 185191.
  9. Soares IS, Levitus G, Souza JM, Del Portillo HA, Rodrigues MM, , 1997. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun 65: 16061614.
  10. Holder AA, Blackman MJ, Burghaus PA, Chappel JA, Ling IT, McCallum-Deighton N, Shai S, , 1992. A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz 87 (Suppl 3): 3742.[Crossref]
  11. Holder AA, , 1988. The precursor to major merozoite surface antigens: structure and role in immunity. Prog Allergy 41: 7297.
  12. McBride JS, Newbold CI, Anand R, , 1985. Polymorphism of a high molecular weight schizont antigen of the human malaria parasite Plasmodium falciparum . J Exp Med 161: 160180.[Crossref]
  13. Putaporntip C, Jongwutiwes S, Sakihama N, Ferreira MU, Kho WG, Kaneko A, Kanbara H, Hattori T, Tanabe K, , 2002. Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus. Proc Natl Acad Sci USA 99: 1634816353.[Crossref]
  14. Tanabe K, Mackay M, Goman M, Scaife JG, , 1987. Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum . J Mol Biol 195: 273287.[Crossref]
  15. Gentz R, Certa U, Takacs B, Matile H, Dobeli H, Pink R, Mackay M, Bone N, Scaife JG, , 1988. Major surface antigen p190 of Plasmodium falciparum: detection of common epitopes present in a variety of plasmodia isolates. EMBO J 7: 225230.
  16. Strych W, Miettinen-Baumann A, Lottspeich F, Heidrich HG, , 1987. Isolation and characterization of the 80,000 dalton Plasmodium falciparum merozoite surface antigen. Parasitol Res 73: 435441.[Crossref]
  17. Guttinger M, Romagnoli P, Vandel L, Meloen R, Takacs B, Pink JR, Sinigaglia F, , 1991. HLA polymorphism and T cell recognition of a conserved region of p190, a malaria vaccine candidate. Int Immunol 3: 899906.[Crossref]
  18. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP, , 2002. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185: 820827.[Crossref]
  19. Herrera-Arévalo M, Rosero F, Herrera S, Caspers P, Rotmann D, Sinigaglia F, Certa U, , 1992. Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection. Infect Immun 60: 154158.
  20. Valderrama-Aguirre A, Quintero G, Gomez A, Castellanos A, Perez Y, Mendez F, Arevalo-Herrera M, Herrera S, , 2005. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg 73: 1624.
  21. Mertens F, Levitus G, Camargo LM, Ferreira MU, Dutra AP, Del Portillo HA, , 1993. Longitudinal study of naturally acquired humoral immune responses against the merozoite surface protein 1 of Plasmodium vivax in patients from Rondonia, Brazil. Am J Trop Med Hyg 49: 383392.
  22. Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LHP, Camargo EP, , 2002. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am J Trop Med Hyg 66: 641648.
  23. Coura JR, Suarez-Mutis M, Ladeia-Andrade S, , 2006. A new challenge for malaria control in Brazil: asymptomatic Plasmodium infection—a review. Mem Inst Oswaldo Cruz 101: 229237.
  24. Brazilian Ministry of Health, 2005. Malaria Diagnosis. Available at: http://portal.saude.gov.br/portal/arquivos/pdf/manual_diag_malaria.pdf. Accessed October 25, 2006.
  25. Kimura M, Kneko O, Liu Q, Zhou M, Kawamoto F, Wataya Y, Otani S, Yamaguchi Y, Tanake K, , 1997. Identification of the four species of human malaria parasites by nested PCR that targets variant sequences in the small subunit rRNA gene. Parasitol Int 46: 9195.[Crossref]
  26. Herrera S, Gomez A, Vera O, Vergara J, Valderrama-Aguirre A, Maestre A, Mendez F, Wang R, Chitnis CE, Yazdani SS, Arevalo-Herrera M, , 2005. Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast. Am J Trop Med Hyg 73: 4449.
  27. Barbedo MB, Ricci R, Jimenez MC, Cunha MG, Yazdani SS, Chitnis CE, Rodrigues MM, Soares IS, , 2007. Comparative recognition by human IgG antibodies of recombinant proteins representing three asexual erythrocytic stage vaccine candidates of Plasmodium vivax . Mem Inst Oswaldo Cruz 102: 335339.[Crossref]
  28. Soares IS, da Cunha MG, Silva MN, Souza JM, Del Portillo HA, Rodrigues MM, , 1999. Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1. Am J Trop Med Hyg 60: 357363.
  29. Dent AE, Chelimo K, Sumba PO, Spring MD, Crabb BS, Moormann AM, Tisch DJ, Kazura JW, , 2009. Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults. Malar J 8: 162.[Crossref]
  30. Pitabut N, Panichakorn J, Mahakunkijcharoen Y, Hirunpetcharat C, Looareesuwan S, Khusmith S, , 2007. IgG antibody profile to c-terminal region of Plasmodium vivax merozoite surface protein-1 in Thai individuals exposed to malaria. Southeast Asian J Trop Med Public Health 38: 17.
  31. Wickramarachchi T, Premaratne PH, Perera KL, Bandara S, Kocken CH, Thomas AW, Handunnetti SM, Udagama-Randeniya PV, , 2006. Natural human antibody responses to Plasmodium vivax apical membrane antigen 1 under low transmission and unstable malaria conditions in Sri Lanka. Infect Immun 74: 798801.[Crossref]
  32. Zeyrek FY, Babaoglu A, Demirel S, Erdogan DD, Ak M, Korkmaz M, Coban C, , 2008. Analysis of naturally acquired antibody responses to the 19-kd C-terminal region of merozoite surface protein-1 of Plasmodium vivax from individuals in Sanliurfa, Turkey. Am J Trop Med Hyg 78: 729732.
  33. Chappel JA, Holder AA, , 1993. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognize the first growth factor-like domain of merozoite surface protein-1. Mol Biochem Parasitol 60: 303311.[Crossref]
  34. Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patino JA, Angov E, Ling IT, Fegeding K, Morgan WD, Ockenhouse C, Birdsall B, Feeney J, Lyon JA, Holder AA, , 2001. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum . J Mol Biol 307: 13811394.[Crossref]
  35. Egan AF, Blackman MJ, Kaslow DC, , 2000. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys. Infect Immun 68: 14181427.[Crossref]
  36. Levitus G, Mertens F, Speranca MA, Camargo LM, Ferreira MU, del Portillo HA, , 1994. Characterization of naturally acquired human IgG responses against the N-terminal region of the merozoite surface protein 1 of Plasmodium vivax . Am J Trop Med Hyg 51: 6876.
  37. Murhandarwati EE, Wang L, Black CG, Nhan DH, Richie TL, Coppel RL, , 2009. Inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam. Infect Immun 77: 45104517.[Crossref]
  38. Bastos MS, Silva-Nunes M, Malafronte RS, Hoffman EH, Wunderlich G, Moraes SL, Fereira UM, , 2007. Antigenic polymorphism and naturally acquired antibodies to Plasmodium vivax merozoite surface protein 1 in Rural Amazonians. Clin Vaccine Immunol 14: 12491259.[Crossref]
  39. Ceravolo IP, Bruna-Romero O, Braga EM, Fontes CJ, Brito CF, Souza JM, Krettli AU, Adams JH, Carvalho LH, , 2005. Anti-Plasmodium vivax duffy binding protein antibodies measure exposure to malaria in the Brazilian Amazon. Am J Trop Med Hyg 72: 675681.
  40. Ceravolo IP, Sanchez BA, Sousa TN, Guerra BM, Soares IS, Braga EM, McHenry AM, Adams JH, Brito CF, Carvalho LH, , 2009. Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin Exp Immunol 156: 502510.[Crossref]
  41. Rodrigues MH, Rodrigues KM, Oliveira TR, Comodo AN, Rodrigues MM, Kocken CH, Thomas AW, Soares IS, , 2005. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1. Int J Parasitol 35: 185192.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2011.10-0044
Loading
/content/journals/10.4269/ajtmh.2011.10-0044
Loading

Data & Media loading...

  • Received : 21 Jan 2010
  • Accepted : 19 Apr 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error